Literature DB >> 25958245

Discovery of bisamide-heterocycles as inhibitors of scavenger receptor BI (SR-BI)-mediated lipid uptake.

Chris Dockendorff1, Patrick W Faloon2, Andrew Germain2, Miao Yu3, Willmen Youngsaye2, Partha P Nag2, Melissa Bennion2, Marsha Penman3, Thomas J F Nieland3, Sivaraman Dandapani2, José R Perez2, Benito Munoz2, Michelle A Palmer2, Stuart L Schreiber4, Monty Krieger5.   

Abstract

A new series of potent inhibitors of cellular lipid uptake from HDL particles mediated by scavenger receptor, class B, type I (SR-BI) was identified. The series was identified via a high-throughput screen of the National Institutes of Health Molecular Libraries Small Molecule Repository (NIH MLSMR) that measured the transfer of the fluorescent lipid DiI from HDL particles to CHO cells overexpressing SR-BI. The series is characterized by a linear peptidomimetic scaffold with two adjacent amide groups, as well as an aryl-substituted heterocycle. Analogs of the initial hit were rapidly prepared via Ugi 4-component reaction, and select enantiopure compounds were prepared via a stepwise sequence. Structure-activity relationship (SAR) studies suggest an oxygenated arene is preferred at the western end of the molecule, as well as highly lipophilic substituents on the central and eastern nitrogens. Compound 5e, with (R)-stereochemistry at the central carbon, was designated as probe ML279. Mechanistic studies indicate that ML279 stabilizes the interaction of HDL particles with SR-BI, and its effect is reversible. It shows good potency (IC50=17 nM), is non-toxic, plasma stable, and has improved solubility over our alternative probe ML278.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Cholesterol transport; HCV; HDL receptor; ML279; SR-BI inhibitor

Mesh:

Substances:

Year:  2015        PMID: 25958245      PMCID: PMC4469081          DOI: 10.1016/j.bmcl.2015.03.074

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  28 in total

1.  Identification of scavenger receptor SR-BI as a high density lipoprotein receptor.

Authors:  S Acton; A Rigotti; K T Landschulz; S Xu; H H Hobbs; M Krieger
Journal:  Science       Date:  1996-01-26       Impact factor: 47.728

2.  Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptor SR-BI.

Authors:  Thomas J F Nieland; Marsha Penman; Limor Dori; Monty Krieger; Tomas Kirchhausen
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-18       Impact factor: 11.205

3.  Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology.

Authors:  B Trigatti; H Rayburn; M Viñals; A Braun; H Miettinen; M Penman; M Hertz; M Schrenzel; L Amigo; A Rigotti; M Krieger
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

4.  The use of the Ugi four-component condensation.

Authors:  Stefano Marcaccini; Tomás Torroba
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

5.  High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I.

Authors:  Cécile Voisset; Nathalie Callens; Emmanuelle Blanchard; Anne Op De Beeck; Jean Dubuisson; Ngoc Vu-Dac
Journal:  J Biol Chem       Date:  2005-01-04       Impact factor: 5.157

6.  Discovery of ITX 4520: a highly potent orally bioavailable hepatitis C virus entry inhibitor.

Authors:  Gopi Kumar Mittapalli; Fang Zhao; Andrew Jackson; Hongfeng Gao; Haekyung Lee; Stephine Chow; Maninder Pal Kaur; Natalie Nguyen; Robert Zamboni; Jeffrey McKelvy; Flossie Wong-Staal; James E Macdonald
Journal:  Bioorg Med Chem Lett       Date:  2012-06-19       Impact factor: 2.823

7.  Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study.

Authors:  Mark S Sulkowski; Minhee Kang; Roy Matining; David Wyles; Victoria A Johnson; Gene D Morse; Valerianna Amorosa; Debika Bhattacharya; Kristine Coughlin; Flossie Wong-Staal; Marshall J Glesby
Journal:  J Infect Dis       Date:  2013-09-16       Impact factor: 5.226

Review 8.  The role of the high-density lipoprotein receptor SR-BI in the lipid metabolism of endocrine and other tissues.

Authors:  Attilio Rigotti; Helena E Miettinen; Monty Krieger
Journal:  Endocr Rev       Date:  2003-06       Impact factor: 19.871

9.  Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor.

Authors:  David Masson; Masahiro Koseki; Minako Ishibashi; Christopher J Larson; Stephen G Miller; Bernard D King; Alan R Tall
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-10-08       Impact factor: 8.311

10.  Mechanism and regulatory function of CpG signaling via scavenger receptor B1 in primary B cells.

Authors:  Peimin Zhu; Xiaohong Liu; Laura S Treml; Michael P Cancro; Bruce D Freedman
Journal:  J Biol Chem       Date:  2009-06-19       Impact factor: 5.157

View more
  3 in total

1.  Benzo-fused lactams from a diversity-oriented synthesis (DOS) library as inhibitors of scavenger receptor BI (SR-BI)-mediated lipid uptake.

Authors:  Chris Dockendorff; Patrick W Faloon; Jun Pu; Miao Yu; Stephen Johnston; Melissa Bennion; Marsha Penman; Thomas J F Nieland; Sivaraman Dandapani; José R Perez; Benito Munoz; Michelle A Palmer; Stuart L Schreiber; Monty Krieger
Journal:  Bioorg Med Chem Lett       Date:  2015-04-01       Impact factor: 2.823

Review 2.  Rediscovering scavenger receptor type BI: surprising new roles for the HDL receptor.

Authors:  Menno Hoekstra; Mary Sorci-Thomas
Journal:  Curr Opin Lipidol       Date:  2017-06       Impact factor: 4.776

3.  Design, Synthesis, and SAR of Novel 2-Glycinamide Cyclohexyl Sulfonamide Derivatives against Botrytis cinerea.

Authors:  Nan Cai; Caixiu Liu; Zhihui Feng; Xinghai Li; Zhiqiu Qi; Mingshan Ji; Peiwen Qin; Wasim Ahmed; Zining Cui
Journal:  Molecules       Date:  2018-03-23       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.